Advanced Therapies in Crohn's Disease
Not currently approved for paediatric use.
Clinical trial analysis in this limited patient population found no clinically meaningful difference in risankizumab exposure between patients 65 years of age or older and adult population.
Women with IBD who are pregnant or attempting conception should continue anti-IL23 therapy throughout pregnancy.13